Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. AbbVie. News release: AbbVie’s upadacitinib granted breakthrough therapy designation from the U.S. Food and Drug Administration for atopic dermatitis. 2018 Jan 8.
2. Staff. Brief—third Australian indication approved for Orencia. ThePharmaLetter. 2018 Jan 22.
3. Braeburn Pharmaceuticals. News release: Braeburn receives complete response letter for CAM2038 injectable buprenorphine depot. 2018 Jan 21.